Bioventus (BVS)
(Delayed Data from NSDQ)
$6.18 USD
-0.34 (-5.21%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $6.18 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth B Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BVS 6.18 -0.34(-5.21%)
Will BVS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BVS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BVS
Do Options Traders Know Something About Bioventus Stock We Don't?
Bioventus (BVS) Q1 Earnings and Revenues Surpass Estimates
BVS: What are Zacks experts saying now?
Zacks Private Portfolio Services
4 Healthcare Stocks to Buy as the Sector Faces Government Heat
Ensign Group Invests in Growth With New Facility Acquisitions
Here's Why Bioventus (BVS) Is a Great 'Buy the Bottom' Stock Now
Other News for BVS
Bioventus gets FDA nod for pain management devices
Bioventus (BVS) Gains FDA Clearance for Pain Management Devices
Bioventus Receives FDA 510(k) Clearances for two Next-Generation Peripheral Nerve Stimulation ...
Bioventus receives FDA 510k clearances for two next-gen PNS products
Bioventus to Report Second Quarter of Fiscal Year 2025 Financial Results on August 6, 2025 | ...